US Patent

US7851502 — Pharmaceutical formulations containing an SGLT2 inhibitor

Formulation · Assigned to Bristol Myers Squibb Co · Expires 2028-08-19 · 2y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical formulations in the form of capsules or tablets for oral use containing dapagliflozin or its propylene glycol hydrate for immediate release.

USPTO Abstract

Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.

Drugs covered by this patent

Patent Metadata

Patent number
US7851502
Jurisdiction
US
Classification
Formulation
Expires
2028-08-19
Drug substance claim
No
Drug product claim
Yes
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.